Goldman Sachs lowered the firm’s price target on Dover to $154 from $161 and keeps a Buy rating on the shares. The company lowered its FY23 guide primarily on lower Biopharma demand, which is “reasonable “, the analyst tells investors in a research note. The firm adds that beyond 2023, Goldman Sachs is lowering its estimates given weaker growth and limited visibility in a few segments, reducing its FY23/FY24/FY25 EPS to $8.80/$9.40/$10.20 from 8.85/$9.70/$10.55 respectively.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DOV:
- Dover price target lowered to $145 from $149 at RBC Capital
- Dover price target lowered to $162 from $165 at Mizuho
- Dover price target lowered to $167 from $184 at Citi
- Dover price target lowered to $156 from $174 at Baird
- Dover cuts FY23 adjusted EPS view to $8.75-$8.85 from $8.85-$9.05
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue